Keyword : PD-L1-negative
Pembrolizumab plus chemotherapy for metastatic NSCLC with programmed cell death ligand 1 tumor proportion score <1%: pooled analysis of outcomes after five years of follow-up
|
|
|
|
|
Keyword : PD-L1-negative |
|